{"id":"W4236289131","doi":"10.1016/s1470-2045(21)00073-5","title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":416,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck; AstraZeneca","keywords":"Olaparib; Medicine; BRCA mutation; Internal medicine; Clinical endpoint; Ovarian cancer; Oncology; Placebo; Progression-free survival; PARP inhibitor; Randomized controlled trial; Cancer; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001287344,0.0002802238,0.002061547,0.0003138432,0.0001008636,0.00002252634,0.000114421,0.0002185501,0.0003291141],"category_scores_gemma":[0.0002410898,0.000184655,0.0001777709,0.001153883,0.0002892345,0.00009859209,0.00002881849,0.0004792101,0.000003148457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003670827,"about_ca_system_score_gemma":0.0009201419,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000499985,"about_ca_topic_score_gemma":0.00124039,"domain_scores_codex":[0.9971963,0.0007050096,0.0007692005,0.0004976022,0.0003881238,0.0004438325],"domain_scores_gemma":[0.9971926,0.001058625,0.0006860362,0.0004408003,0.000522828,0.00009906299],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9821005,0.001081023,0.002179453,0.00002202355,0.003164578,0.0001772732,0.002687767,0.0005248552,0.001478194,0.0003591828,0.0002748874,0.005950271],"study_design_scores_gemma":[0.9836938,0.00415537,0.006467306,0.0001378844,0.001342671,0.00004474492,0.0003035956,0.00110283,0.001685781,0.0001329979,0.0007358519,0.0001971319],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885744,0.0003609026,0.0002793561,0.004746426,0.0002231716,0.003907245,0.0001127913,0.00002938351,0.001766298],"genre_scores_gemma":[0.9944612,0.0005291211,0.0004399485,0.002406079,0.0003057439,0.001345311,0.0001878175,0.00002857634,0.0002961392],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005886838,"threshold_uncertainty_score":0.7530012,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05218418572592092,"score_gpt":0.3670435714528127,"score_spread":0.3148593857268918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}